Despite Shanghai ZJ Bio-Tech's poor revenue, its P/S ratio aligns with the industry, indicating investors might be ignoring recent negative growth and hoping for a business turnaround. However, if medium-term revenue trends persist, this could risk shareholders' investments and potential investors might pay an unnecessary premium.